netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Pembrolizumab found 23 matches

Formulary items 1 match
   
Open monograph to display formulary status BNF Category
  Cytotoxic Drug Pembrolizumab  (Keytruda®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA Drug Safety Update (July 2017): Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection (08.01.05)
link in drug section MHRA Drug Safety Update (July 2017): Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection (08.01.05)
link in drug section NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (08.01.05)
link in drug section NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (08.01.05)
link in drug section NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab (08.01.05)
link in drug section NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (08.01.05)
link in drug section NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (08.01.05)
link in drug section NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (08.01.05)
link in drug section NICE TA683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (08.01.05)
link in drug section NICE TA692: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (08.01.05)
link in drug section NICE TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (08.01.05)
link in drug section NICE TA737: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer (08.01.05)
link in drug section NICE TA766: Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (08.01.05)
link in drug section NICE TA770: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (08.01.05)
link in drug section NICE TA772: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies (08.01.05)
link in drug section NICE TA801: Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (08.01.05)
link in drug section NICE TA830: Pembrolizumab for adjuvant treatment of renal cell carcinoma (08.01.05)
link in drug section NICE TA837: Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (08.01.05)
link in drug section NICE TA885: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (08.01.05)
link in drug section NICE TA904: Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (08.01.05)
link in drug section NICE TA914: Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (08.01.05)
link in drug section NICE TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (08.01.05)


 
netFormulary